Akari Therapeutics, Plc announced that it has entered into a definitive agreement with individual investors such as Ray Prudo and Samir R. Patel, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 4,029,754 unregistered American Depository Shares each representing 2,000 of the Company?s ordinary shares and Series C Warrants to purchase up to 4,029,754 ADSs, at a per unit price of $1.885 per ADS and Warrant for the aggregate gross proceeds of $15,192,172 on May 29, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.72 USD | -1.81% |
|
-4.06% | -12.82% |
1st Jan change | Capi. | |
---|---|---|
-12.82% | 32.52M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- AKTX Stock
- News Akari Therapeutics, Plc
- Akari Therapeutics, Plc announced that it expects to receive $15.192172 million in funding